In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nonprescription headache remedies save consumers $4.23 bil. annually -- Kline study.

This article was originally published in The Tan Sheet

Executive Summary

Rx-to-OTC SWITCH PRODUCTS SAVED CONSUMERS $12.88 BIL. IN 1996, according to a study conducted by Fairfield, N.J.-based Kline & Company for the Nonprescription Drug Manufacturers Association. Presented at NDMA's May 15-18 annual meeting in White Sulphur Springs, W.Va., the study found that the savings generated by switch products represented 63% of the total savings attributable to OTCs. "It is clear that the Rx-to-OTC switch process contributes greatly to the continued value of OTC products," Kline maintained





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts